A detailed history of Eads & Heald Wealth Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Eads & Heald Wealth Management holds 3,847 shares of GILD stock, worth $256,556. This represents 0.13% of its overall portfolio holdings.

Number of Shares
3,847
Previous 3,536 8.8%
Holding current value
$256,556
Previous $286,000 1.4%
% of portfolio
0.13%
Previous 0.14%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$71.58 - $87.29 $22,261 - $27,147
311 Added 8.8%
3,847 $282,000
Q4 2023

Jan 30, 2024

SELL
$73.27 - $83.09 $3,516 - $3,988
-48 Reduced 1.34%
3,536 $286,000
Q3 2023

Oct 27, 2023

SELL
$73.94 - $80.67 $1,109 - $1,210
-15 Reduced 0.42%
3,584 $269,000
Q2 2023

Jul 25, 2023

SELL
$76.01 - $86.7 $8,057 - $9,190
-106 Reduced 2.86%
3,599 $277,000
Q1 2023

Apr 21, 2023

BUY
$77.31 - $88.08 $28,991 - $33,030
375 Added 11.26%
3,705 $307,000
Q4 2022

Jan 27, 2023

SELL
$62.32 - $89.47 $65,436 - $93,943
-1,050 Reduced 23.97%
3,330 $286,000
Q3 2022

Oct 27, 2022

BUY
$59.54 - $68.01 $31,556 - $36,045
530 Added 13.77%
4,380 $270,000
Q2 2022

Jul 26, 2022

BUY
$57.72 - $65.01 $222,222 - $250,288
3,850 New
3,850 $237,000
Q1 2022

Apr 27, 2022

SELL
$57.92 - $72.58 $255,890 - $320,658
-4,418 Closed
0 $0
Q4 2021

Jan 31, 2022

BUY
$64.88 - $73.64 $2,011 - $2,282
31 Added 0.71%
4,418 $320,000
Q3 2021

Oct 27, 2021

BUY
$67.69 - $73.03 $71,142 - $76,754
1,051 Added 31.5%
4,387 $306,000
Q2 2021

Jul 30, 2021

BUY
$63.47 - $69.35 $14,153 - $15,465
223 Added 7.16%
3,336 $229,000
Q1 2021

Apr 29, 2021

BUY
$60.0 - $68.46 $186,780 - $213,115
3,113 New
3,113 $201,000
Q4 2020

Feb 02, 2021

SELL
$56.65 - $64.55 $182,866 - $208,367
-3,228 Closed
0 $0
Q3 2020

Nov 02, 2020

BUY
$62.1 - $78.08 $200,458 - $252,042
3,228 New
3,228 $203,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $83.6B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Eads & Heald Wealth Management Portfolio

Follow Eads & Heald Wealth Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eads & Heald Wealth Management, based on Form 13F filings with the SEC.

News

Stay updated on Eads & Heald Wealth Management with notifications on news.